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Introduction: Previous studies showed that quarantine for pandemic diseases is
associated with several psychological and medical effects. The consequences of
quarantine for COVID-19 pandemic in patients with dementia are unknown. We
investigated the clinical changes in patients with Alzheimer’s disease and other
dementias, and evaluated caregivers’ distress during COVID-19 quarantine.
Methods: The study involved 87 Italian Dementia Centers. Patients with Alzheimer’s
Disease (AD), Dementia with Lewy Bodies (DLB), Frontotemporal Dementia (FTD), and
Vascular Dementia (VD) were eligible for the study. Family caregivers of patients with
dementia were interviewed by phone in April 2020, 45 days after quarantine declaration.
Main outcomes were patients’ changes in cognitive, behavioral, and motor symptoms.
Secondary outcomes were effects on caregivers’ psychological features.
Results: 4913 patients (2934 females, 1979 males) fulfilled the inclusion criteria.
Caregivers reported a worsening in cognitive functions in 55.1% of patients, mainly
in subjects with DLB and AD. Aggravation of behavioral symptoms was observed in
51.9% of patients. In logistic regression analysis, previous physical independence was
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associated with both cognitive and behavioral worsening (odds ratio 1.85 [95% CI 1.42–
2.39], 1.84 [95% CI 1.43–2.38], respectively). On the contrary, pandemic awareness
was a protective factor for the worsening of cognitive and behavioral symptoms
(odds ratio 0.74 [95% CI 0.65–0.85]; and 0.72 [95% CI 0.63–0.82], respectively).
Approximately 25.9% of patients showed the onset of new behavioral symptoms.
A worsening in motor function was reported by 36.7% of patients. Finally, caregivers
reported a high increase in anxiety, depression, and distress.
Conclusion: Our study shows that quarantine for COVID-19 is associated with an
acute worsening of clinical symptoms in patients with dementia as well as increase of
caregivers’ burden. Our findings emphasize the importance to implement new strategies
to mitigate the effects of quarantine in patients with dementia.
Keywords: quarantine, COVID-19, dementia, Alzheimer’s disease, BPSD, caregiver burden
INTRODUCTION
The coronavirus disease 2019 (COVID-19) pandemic is,
nowadays, a global public health emergency (Palacios Cruz et al.,
2020). By December 8, 2020, over 66 million confirmed cases
of COVID-19 with more than 1.530.000 deaths worldwide have
been reported to the World Health Organization. Older adults
and patients with certain comorbidities, many of whom are
of advanced age, are particularly susceptible to more severe
consequences of the disease (Shahid et al., 2020). The impact
of the pandemic to the healthcare systems has been disruptive,
and prevention as well as treatment services for patients with
non-communicable diseases have been severely reduced.
Trying to slow down the spread of pandemic, several
governments launched mitigation strategies, based mainly on
quarantine. Quarantine is efficacious in reducing incidence
and mortality during outbreaks of infectious diseases, and
preliminary indications suggest that this strategy is effective also
in the COVID-19 pandemic (Nussbaumer-Streit et al., 2020).
However, home confinement is an unpleasant experience, due
to the significant limitations in physical, cognitive, and social
activities. Studies related to the 2003 outbreak of severe acute
respiratory syndrome (SARS) in China and Canada, as well
as the 2014 Ebola outbreak in Africa, showed that quarantine
is associated with several negative psychological effects, like
depression, irritability, anger, and insomnia (Hawryluck et al.,
2004; Barbisch et al., 2015; Brooks et al., 2020; Gualano et al.,
2020). Deaths by suicide increased in older adults during the
SARS epidemic in Hong Kong (Cheung et al., 2008). In addition,
long-lasting psychiatric effects of quarantine have been reported
(Mak et al., 2009).
Individuals with Alzheimer’s disease and other dementias
are among the most vulnerable persons in the society, and the
COVID-19 outbreak is likely to have further exacerbated their
frailty (Wang et al., 2020). Quarantine effects in dementia patients
and family caregivers have never been adequately investigated.
All the negative effects of quarantine previously reported may
be exacerbated in individuals with dementia, whose physical and
social isolation may amplify the functional limitations and the
pre-existing conflicts within the family. Patients with dementia
living at home significantly depend on family caregivers for
assistance, and caring for dementia patients causes a significant
burden in caregivers (Chiao et al., 2015; Raggi et al., 2015; Brown
et al., 2020). Higher levels of cognitive, behavioral and motor
impairment in patients with dementia are associated with greater
burden and distress in their caregivers (Black et al., 2018; Yang
et al., 2019; Xiong et al., 2020). Therefore, there is an urgent
need to investigate clinical and psychological changes due to
quarantine in patients with dementia and their caregivers.
This study aimed at evaluating the effects of quarantine in
Italian patients with different types and severity of dementia
and their caregivers. Approximately 45 days after quarantine
declaration by the Italian government, we interviewed the
family caregivers of persons with dementia referring to several
Italian Centers for Cognitive Disorders and Dementia (CDCDs),
investigating patients’ variations in cognitive, behavioral, and
motor symptoms. Besides, we evaluated the changes in prescribed
medications, caregiver’s burden, and changes in health services
provided by the Italian National Health Service.
MATERIALS AND METHODS
Study Design, Centers and Participants
This is a multicentric, nation-wide survey. Eighty-nine Italian
CDCDs were initially recruited for the study. First of all, a
semi-structured questionnaire (see Supplementary Material)
was administered to the Director of each Centre in order
to evaluate its qualitative and quantitative characteristics, and
variations in clinical activities after quarantine declaration. Due
to the quarantine rules, all the out-patients visits were stopped.
Therefore, the clinical staff members of each CDCD consecutively
contacted by phone the family caregivers of patients registered
in the waiting list. After an oral consent, a semi-structured, self-
made interview gathering demographic and clinical data on the
patient and the caregiver was administered (see Supplementary
Material). Inclusion criteria were a diagnosis of one of the
most common forms of dementias including: (1) Alzheimer’s
Disease (AD), (2) Dementia with Lewy Bodies (DLB), (3)
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Frontotemporal Dementias (FTD), and (4) Vascular Dementia
(VD). Exclusion criteria included current or previous diagnosis
of other forms of dementias, mild cognitive impairment, and
subjective cognitive complaints.
Description of the Survey
We collected all the socio-demographic characteristics of
patients. The stage of dementia was assessed using the
Clinical Dementia Rating (CDR) (Morris et al., 1997) scale.
Furthermore, we investigated the patient’s variation in his/her
clinical status, analyzing cognitive, psychological, behavioral,
and motor symptoms during the quarantine period. Briefly,
the following cognitive features were investigated: changes in
memory, spatial and temporal orientation, language, attention,
and perception. Questions about patient’s awareness of the
pandemic were administered. In addition, we acquired data
regarding variations in behavioral and psychological symptoms
of dementia (BPSD, i.e., irritability, apathy, agitation, anxiety,
depression, sleep change, aggressiveness, wandering, appetite
change, hallucinations, and delusions), reporting for these
symptoms both a worsening and/or a new onset that occurred
during the quarantine period. Further questions about the
need for modifying therapy because of BPSD changes were
administered. Finally, we investigated the changes in patients’
motor activity, evaluating through a 5-point ordinal scale specific
question if the subject walked better from the beginning of
the quarantine period, remained stable, walked slower, became
wheelchair, or became confined to bed.
Caregivers’ Socio-Demographic
Characteristics
Caregivers’ were asked about the cohabitation with the patient,
composition of the family, and own work activity. Other
questions concerned the impact of the quarantine period on
caring for a person with dementia on their caregivers’ lives,
investigating both social and psychological effects (changes in
caregiver’s life, change in the relationship with the patient,
concern for the pandemic, changes in therapeutic assistance, need
to seek help from the emergency department, use of telemedicine,
need to support during quarantine, own feeling of depression,
anxiety, irritability, distress, overwhelm, and abandonment).
Further details are available at Supplementary Material.
Statistical Analysis
We performed statistical analysis using SPSS software, version 21,
and the R statistical computing environment, version 3.6.2 (IBM
Corp, 2012; R Core Team, 2013). Due to the low rate of missing
data (<1%) no imputation was made. Firstly, we performed
a descriptive analysis of all the demographic and clinical
data. Then, we performed univariable and multivariable logistic
regression of the dependent variables (outcomes in clinical
symptoms, all described by binary variables) on the collected
independent variables, using mixed effects logistic regression
(as implemented in the lme4 R package) with the center as a
random effect and all other regressors as fixed effects. Regressors
with significant p (<0.05) in univariable logistic regression were
included in multivariable regression. Bonferroni correction was
applied to all the p-values of multivariable analysis, considering
all outcomes together, as multivariable analysis is considered as
our final result. We controlled for caregiver stress by including it
in the multivariable analysis as a confounder, as a numerical fixed
effect. The level of statistical significance was set at p < 0.05.
Ethical Standards
The study was initially approved by the Ethics Committee
of the Coordinating Centre (University of Torino on April
7, 2020, n.00150/2020) and then by the local ethics boards.
Caregivers gave first oral and then written fully informed
consent to the study.
RESULTS
Changes in Health Services
The response rate of CDCDs to the proposed questionnaires
was 98%. Only two CDCDs were excluded because they
did not recruit patients. The final 87 recruiting Centers
were homogeneously distributed throughout the Italian
territory (Figure 1).
Thirty-two percent of patients with dementia were recruited
in Northern, 32% in Central, and 36% in Southern Italy.
Thirty percent of CDCDs was based at university hospitals,
34% to general hospitals, and 36% to territorial based health
services. In the pre-COVID-19 pandemic period, each Center
followed a mean of 160 dementia patients per month. After the
quarantine declaration, 85% of the CDCD suspended medical
and psychological appointments, and visits were restricted to
emergencies. Different forms of telemedicine (from phone calls to
videoconferencing) were activated in 78% of Centers. One out of
two Center provided on-line psychological support for caregivers.
All the randomized clinical trials were stopped. Finally, 94% of
support activities for dementia patients (Alzheimer’s café, Day
Center, etc.) were closed.
Caregivers
The Survey response rates of the family caregivers ranged
from 91.3 to 99.1%, according to different dementia Centers.
We interviewed 5321 caregivers of patients regularly followed
at different CDCDs. After data cleaning, the information
collected from 4913 family caregivers (women 2934,
mean age ± SD = 58.2 ± 12.0 years; men 1979, mean
age ± SD = 60.7 ± 13.9 years) were analyzed. Fifty-nine %
were cohabitants with the patients, and 36% were spouses of the
dementia care recipient. Approximately half of the caregivers
reported that quarantine induced a significant change in their
lifestyle, with 30.3% complaining a reduction in time devoted
to their own activities, and 15.5% reporting an increase in
intrafamilial psychological conflicts. Caregivers reported a
significant increase in anxiety (45.9%), depression (18.6%),
irritability (26.2%), and distress (28.9%). Finally, 80.8% of
the caregivers reported that telemedicine has been of help
during quarantine.
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FIGURE 1 | Regional distribution of the Dementia Centers involved in the SINdem COVID-19 study. Within brackets, the number of Centers in each city.
Dementia Patients
From April 14 to April 27, 2020, we collected data
regarding 4913 patients with dementia (2934 females,
mean age ± SD = 78.9 ± 8.2 years; 1979 males, mean
age ± SD = 77.2 ± 8.0 years) regularly followed at CDCDs.
Demographic and clinical characteristics of dementia patients
are shown in Table 1.
Family caregivers reported that, after a quarantine period of
approximately 47 days, dementia patients showed a worsening
in cognitive symptoms (+55.1%), and behavioral symptoms
(+51.9%), the onset of new behavioral symptoms (+25.9%),
and an increase in motor symptoms (+36.7%). According to
caregivers, 40.1% of patients were totally aware of quarantine
declaration, 36.0% were only partially aware, while 23.9%
were totally unaware. Awareness of the quarantine varied
significantly among the dementia subgroups, with DLB
patients showing the highest degree (69.8%) of partial of total
unawareness of pandemic.
Changes in Cognitive Symptoms
Caregivers reported a worsening in cognitive symptoms in
approximately 60% of dementia participants. About 37% of
dementia participants showed worsening in two or more
cognitive domains. Deficits more often reported as increased
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Age (years, mean ± SD) 78.3 ± 8.2 78.3 ± 8.0 78 ± 7.3 72.3 ± 8.9 81.6 ± 7.0
Sex (female, %) 59.7 63.5 42.2 46.7 58.4
Duration of the disease (years, mean ± SD) 4.5 ± 3.1 4.6 ± 3.1 4.5 ± 3 4.8 ± 3.2 4.1 ± 2.9
Regional distribution
North (%) 32.2 26.5 35.3 47.5 47.8
Centre (%) 31.5 34.1 36.4 21.2 23.4
South - Islands (%) 36.3 39.4 28.3 31.3 28.8
CDR Stage (%)
1 25.0 24.3 26.3 23.4 28.4
2 47.8 49.2 41.9 48.6 43.8
3 27.2 26.5 31.8 28.0 27.8
Duration of the quarantine (days, mean ± SD) 47.2 ± 6.4 47.2 ± 6.5 46.6 ± 5.6 46.4 ± 5.3 47.8 ± 6.8
Changes in cognitive symptoms (Yes, %) 55.1 55.7 59.6 48.3 54.2
Sex (female, %) 58.4 63.0 36.3 44.7 55.2
Changes in BPSD (Yes, %) 51.9 50.5 63.8 55.3 50.3
Sex (female, %) 57.9 62.9 38.4 45.4 55.1
New onset BPSD (Yes, %) 25.9 26.7 23.3 21.9 25.6
Sex (female, %) 56.7 59.8 41.7 41.8 56.1
Changes in motor symptoms (Yes, %) 36.7 33.2 52.8 40.2 42.3
Sex (female, %) 58.6 65.0 44.7 43.1 52.5
Caregivers
Age (years, mean ± SD) 59.3 ± 13 59.3± 13.1 60.7± 12.7 59.1± 13.6 60 ± 12.4
Sex (female, %) 53.9 51.2 66.4 55.4 59.4
Cohabitant caregiver (%) 58.9 58.1 63.5 69.6 54.4
Degree of kinship
Spouses (%) 36.0 35.0 43.1 54.8 26.9
Son/daughter (%) 54.5 55.5 48.7 37 62.5
Others (%) 9.5 9.5 8.2 8.2 10.6
Increase in anxiety (%) 45.9 46.1 43.4 44.2 47.4
Increase in depression (%) 18.6 17.2 21.3 24.3 20.3
AD, Alzheimer’s disease; DLB, Dementia with Lewy Bodies; FTD, frontotemporal dementia; VD, vascular dementia; CDR, Clinical Dementia Rating; BPSD, Behavioral and
Psychological symptoms of dementia.
were: forgetfulness (68%), confusion (67.9%), and temporal
disorientation (37%). Figure 2 displays the frequency distribution
of cognitive symptoms worsened during quarantine.
When we examined diagnostic subgroups, we found a
worsening of cognitive symptoms mainly in patients with
DLB (59.6%) and AD (55.7%), followed by VD (54.2%), and
FTD (48.3%) patients. Thirty-eight % of patients with AD
showed a worsening in memory functions, 37.5% presented
an increase in confusion, and 21.1% showed a worsening in
temporal disorientation. The same effects were observed in
patients with DLB, showing a worsening in memory functions
in 26.1%, an increase in confusion in 40.3%, and in temporal
disorientation in 20.3%. Patients with FTD showed mainly a
worsening in language functions (25.5%). After multivariable
analysis, the increase of cognitive symptoms in the overall
group of patients with dementia was not associated with age,
gender, duration of quarantine, disease severity, and changes
in caregivers’ psychological features. Contrariwise, an inverse
relationship between the aggravation of cognitive symptoms and
the duration of the dementia was found (p < 0.001).
Interestingly, the pre-existing total or partial independence
in motor function represents a risk factor for the worsening of
cognitive functions (OR 1.85 [95% CI 1.42–2.39], p < 0.001;
and OR 2.08 [95% CI 1.68–2.57], p < 0.001, respectively).
Contrariwise, total awareness of quarantine was a protective
factor against cognitive worsening (OR 0.68 [95% CI 0.57–0.81],
p < 0.001) (Table 2).
Changes in Behavioral Symptoms
During the quarantine period, BPSD worsened in approximately
half of the patients with dementia. The most frequently worsened
BPSD were irritability (40%), followed by apathy (35%), and
agitation (31%) (Figure 3).
Examining subgroups, we found an increase in the number
of symptoms mainly in patients with DLB (63.8%), followed
by FTD (55.3%), AD (50.5%), and VD (50.3%). The increase
of neuropsychiatric symptoms in patients with dementia was
associated with moderate disease severity (CDR 2, p = 0.009), but
not remained significant after applying Bonferroni correction.
The worsening of BPSD was associated with pre-existing total
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FIGURE 2 | Spider-plot of changes in cognitive function during quarantine; dots mark the mean proportion of each symptom.
TABLE 2 | Univariable and multivariable analysis of risk and protective factors for cognitive and motor changes during quarantine in patients with dementia.
Univariable analysis Multivariable analysis
Crude OR (95% CI) P-value Adjusted OR (95% CI) P-value P-value after Bonferroni correction
Changes in cognitive symptoms
Age 1.00 (0.99 – 1.00) 0.24
Sex (men vs. women) 1.15 (1.01 – 1.30) 0.03 1.13 (0.99 – 1.29) 0.07 1
Duration of the disease (years) 0.95 (0.93 – 0.97) <0.001 0.94 (0.92 – 0.97) <0.001 <0.001
Duration of quarantine (days) 1.00 (0.99 – 1.01) 0.97
Disease severity – CDR 2 1.29 (1.11 – 1.50) <0.001 1.19 (1.00 – 1.42) 0.05 1
Disease severity – CDR 3 1.02 (0.86 – 1.21) 0.81 0.93 (0.74 – 1.17) 0.52 1
Total physical independence 1.74 (1.40 – 2.16) <0.001 1.85 (1.42 – 2.39) <0.001 <0.001
Partial physical independence 2.19 (1.80 – 2.67) <0.001 2.08 (1.68 – 2.57) <0.001 <0.001
Total awareness of pandemic 0.74 (0.65 – 0.85) <0.001 0.68 (0.57 – 0.81) <0.001 <0.001
Partial awareness of pandemic 1.39 (1.18 – 1.64) <0.001 1.20 (1.00 – 1.43) 0.05 1
Changes in motor symptoms
Age 1.03 (1.02 – 1.04) <0.001 1.02 (1.01 – 1.03) <0.001 0.001
Sex (men vs. women) 1.11 (0.98 – 1.25) 0.12
Duration of the disease (years) 1.05 (1.03 – 1.07) <0.001 1.00 (0.98 – 1.03) 0.86 1
Duration of quarantine (days) 1.00 (0.99 – 1.01) 0.99
Disease severity – CDR 2 1.94 (1.65 – 2.29) <0.001 1.29 (1.07 – 1.56) 0.009 0.29
Disease severity – CDR 3 3.08 (2.56 – 3.70) <0.001 1.60 (1.26 – 2.02) <0.001 0.004
Total physical independence 0.32 (0.25 – 0.40) <0.001 0.49 (0.37 – 0.64) <0.001 <0.001
Partial physical independence 0.93 (0.77 – 1.12) 0.44 1.06 (0.86 – 1.30) 0.59 1
Total awareness of pandemic 0.44 (0.38 – 0.51) <0.001 0.76 (0.64 – 0.91) 0.003 0.10
Partial awareness of pandemic 0.75 (0.64 – 0.88) <0.001 0.93 (0.78 – 1.10) 0.39 1
OR, Odds ratio; 95% CI, 95% confidence interval; CDR, Clinical Dementia Rating.
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FIGURE 3 | Spider-plot of variations in both clusters (changes and new onset) of behavioral and psychological symptoms; dots mark the mean increase of each
behavior.
or partial autonomy in motor function (totally independent
OR 1.84 [95% CI 1.43–2.38], p < 0.001; partially dependent
OR 1.88 [95% CI 1.53–2.31], p < 0.001). After multivariate
analysis, the worsening of BPSD was not associated with age,
gender, duration of quarantine, disease severity, duration of
disease, and changes in caregivers’ psychological features. On
the contrary, total awareness of the pandemic was inversely
related to worsening of BPSD (OR 0.75 [95% CI 0.63–0.89],
p = 0.03) (Table 3).
New BPSD occurred in approximately a quarter of the
dementia patients. There was a different increase in the frequency
of BPSD across groups. The most frequently reported new
symptom was irritability (21.3%), followed by sleep change
(21%), and agitation (18%) (Figure 2), which required therapy
adjustments. The highest increase was observed in AD (26.7%),
intermediate in VD and DLB (25.6 and 23.3%, respectively),
and the lowest increase in FTD (21.9%). No suicide attempts
were reported. The onset of new BPSD was associated with the
total or partial physical independence (p < 0.001 and p = 0.01,
respectively). Total awareness of the pandemic was inversely
related to onset of new BPSD (OR 0.74, [95% CI 0.62–0.88],
p = 0.03).
Changes in Motor Symptoms
Increased motor dysfunction, mainly characterized by walking
difficulties, was reported by caregivers in 36.7% of the patients.
There was an increase mainly in patients with DLB (52.8%),
followed by VD (42.3%), FTD (40.2%), and AD (33.2%). Age
and disease severity were associated with an increase of motor
dysfunction (p < 0.001) during quarantine, whereas full physical
autonomy before quarantine was a positive predictor against
worsening in motor functions (OR 0.49 [95% CI 0.37–0.64],
p < 0.001).
The increased prevalence of cognitive, behavioral and motor
symptoms was not influenced either by regional distribution of
different CDCD or by the regional prevalence of COVID-19 at
the time of the study.
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TABLE 3 | Univariable and multivariable analysis of risk and protective factors for increase in BPSD and onset of new BPSD during quarantine in patients with dementia.
Univariable analysis Multivariable analysis
Crude OR (95% CI) P-value Adjusted OR (95% CI) P-value P-value after Bonferroni correction
Increase in BPSD
Age 0.99 (0.98 – 0.99) <0.001 0.99 (0.98 – 0.99) 0.005 0.16
Sex (men vs. women) 1.17 (1.04 – 1.32) 0.008 1.12 (0.99 – 1.28) 0.08 1
Duration of the disease (years) 0.98 (0.96 – 0.99) 0.04 0.97 (0.95 – 0.99) 0.01 0.48
Duration of quarantine (days) 0.99 (0.99 – 1.01) 0.66
Disease severity – CDR 2 1.33 (1.15 – 1.54) <0.001 1.26 (1.06 – 1.49) 0.009 0.30
Disease severity – CDR 3 1.32 (1.12 – 1.56) 0.001 1.21 (0.97 – 1.52) 0.09 1
Total physical independence 1.56 (1.26 – 1.93) <0.001 1.84 (1.43 – 2.38) <0.001 <0.001
Partial physical independence 1.90 (1.57 – 2.30) <0.001 1.88 (1.53 – 2.31) <0.001 <0.001
Total awareness of pandemic 0.72 (0.63 – 0.82) <0.001 0.75 (0.63 – 0.89) <0.001 0.03
Partial awareness of pandemic 1.25 (1.07 – 1.45) 0.005 1.20 (1.01 – 1.42) 0.04 1
Onset of new BPSD
Age 1.00 (0.99 – 1.00) 0.32
Sex (men vs. women) 1.19 (1.04 – 1.36) 0.01 1.10 (0.95 – 1.27) 0.21 1
Duration of the disease (years) 0.99 (0.97 – 1.01) 0.41
Duration of quarantine (days) 1.00 (0.99 – 1.01) 0.72
Disease severity – CDR 2 1.14 (0.96 – 1.35) 0.13
Disease severity – CDR 3 1.08 (0.89 – 1.32) 0.41
Total physical independence 1.69 (1.30 – 2.18) <0.001 1.92 (1.45 – 2.55) <0.001 <0.001
Partial physical independence 1.59 (1.26 – 2.02) <0.001 1.55 (1.22 – 1.99) <0.001 0.01
Total awareness of pandemic 0.78 (0.67 – 0.92) 0.003 0.74 (0.62 – 0.88) <0.001 0.03
Partial awareness of pandemic 1.17 (0.99 – 1.39) 0.07 1.10 (0.92 – 1.32) 0.29 1
BPSD, Behavioral and Psychological Symptoms of Dementia; OR, Odds ratio; 95% CI, 95% confidence interval; CDR, Clinical Dementia Rating.
DISCUSSION
Our study shows that quarantine due to COVID-19 pandemic
is associated with a dramatic increase in clinical symptoms of
patients with dementia. According to family caregivers, social
isolation and physical restraint caused a worsening in cognitive
function, an aggravation of several behavioral symptoms, and
a worsening in motor function. These effects were observed in
all forms of dementia, but patients with DLB and AD showed
the highest increase in cognitive and behavioral symptoms. In
addition, the quarantine period was associated with an increase
of caregiver’s burden, mainly characterized by anxiety.
To the best of our knowledge, this is the first nation-
wide study that investigated the effects of quarantine in
patients with dementia. Our data confirm the results of a
previous, small study that investigated the effects of COVID-
19 outbreak in patients with MCI and dementia (Canevelli
et al., 2020). To evaluate factors associated with the quarantine-
related clinical worsening, we performed extensive statistical
analyses, and the most consistent relation was observed with
the pre-pandemic physical status. Patients still able to walk
unassisted or accompanied, after an acute interruption of
physical activity, showed the greater worsening in clinical
symptoms. Sex, age, duration of the disease, and disease severity
had small and inconsistent effects. Several studies showed
that physical activity has a positive impact on cognition of
elderly adults (Fratiglioni et al., 2004; Bherer, 2015; Forbes
et al., 2015; Young et al., 2015) and provided evidence that
in patients with dementia there is an inverse relationship
between physical activity, abnormal behavior, and cognitive
decline (Nelson and Tabet, 2015; Karssemeijer et al., 2017).
Patients physically more independent and, probably, with a
more active life, enriched with a variety of social contacts and
cognitive stimulation, are those most affected by the negative
effects of confinement. Our study highlights the importance
of maintaining physical activity in patients with dementia,
and suggests the need for additional investigations to better
understand this phenomenon.
Our study showed that 40% of the examined patients
were totally aware of the COVID-19 pandemic and of social
and physical restrictive measures planned to control virus
transmission. Intriguingly, we found that patients with dementia
still able to completely understand the need of quarantine, and
therefore able to adopt adequate strategies to face the stress,
had a significantly lower impairment in cognitive, behavioral
and motor function. Contrariwise, less aware patients failed in
creating new adaptive procedures to quarantine. Awareness of
quarantine varied significantly among dementia subgroups and
DLB patients showed the highest degree of partial and total
degree of awareness. Taken together, the results of our study
suggested that DLB patients are the most vulnerable to acute
stress among the patients with dementia.
The neurobiological basis of the observed phenomenon has
never been investigated. Examining subgroups of patients with
dementia, we found an increase mainly of the core symptoms
that characterize different types of dementing illness. This finding
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suggests that the observed phenomenon is not disease-specific
but is more likely attributable to stress-induced changes.
Studies in experimental animals showed that exposure to
both acute and chronic stress evokes chemical changes in
brain that impair the higher cognitive functions (Arnsten
et al., 1999; Yamada et al., 2003). Uncontrollable, acute stress
induces a diffuse increase in brain glucocorticoids and a
specific catecholamine release in prefrontal cortex, impairing
spatial memory tasks (Arnsten, 2015; Bahtiyar et al., 2020).
Intriguingly, in animal models of acute physical and social
restraints, an impairment of serotonin metabolism in the
central nervous system was reported, with an alteration of
immune response (Medina-Martel et al., 2013). In humans,
stress drives several diseases, including cognitive disorders
such as AD (Canet et al., 2019). Acute stress induces a
neuroinflammatory response characterized by the release of
several pro-inflammatory molecules and microglial activation
that is a common feature of several neurodegenerative diseases
(Sharma and Kanneganti, 2016). Finally, worsening of sleep,
frequently reported in our study, is an additional explanation
of our findings. Poor sleep is strongly associated with risk of
multiple types of dementia and, via modulation of β-amyloid
secretion, is directly involved in AD pathogenesis (Vanderheyden
et al., 2018). Further studies are warranted to better elucidate the
neurobiological mechanisms underlying the reported worsening
of patients with dementia during quarantine and to provide
therapeutic strategies.
Caregiving of dementia patients is associated with a higher
prevalence of depressive and anxiety disorders, and impairments
in physical health. Data from our study clearly showed that,
as previously observed in the general population after SARS
and Ebola outbreaks, quarantine is associated with increase in
anxiety and depression. New health policies should be planned
in the post-COVID-19 era to help family caregivers in delivering
effective care. Finally, dementia Centers need to implement
new strategies, as telemedicine (Goodman-Casanova et al., 2020;
Hollander and Carr, 2020), in order to assist frailty people and
support family members.
Some limitations of our study should be acknowledged.
We examined dementia patients living at home and our data
cannot be generalized to institutionalized patients with dementia.
Then, we performed a cross-sectional study and, at present,
it is unclear whether the observed clinical worsening is a
transient or long-lasting phenomenon. Finally, all the clinical
data regarding patient’s symptoms were collected from family
caregivers as, due to quarantine rules, it was not possible
to administer face-to-face standardized neuropsychological
tests. However, previous studies showed that BPSD can be
adequately evaluated by family caregivers and demonstrated
that symptoms reported can be used in the clinical staging of
dementia (Kwok et al., 2011; Yuan et al., 2020). Therefore, in
order to evaluate if there is a time-effect, we have planned
a new follow-up interview to the same caregivers. Finally,
the major strength of our study is the high number of
caregivers that have been interviewed in a relatively small
amount of time and their reliability, having this role from the
onset of dementia.
CONCLUSION
In conclusion, interviewing family caregivers, we investigated
for the first time the acute effects of quarantine in a large
Italian population of patients with dementia, and we found that
restrictive public health measures, are associated with an increase
of dementia symptoms. These findings are important from a
health policy perspective and suggest the need of new health care
strategies to target patients with dementia during pandemic.
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